GLP

R&D

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.